Clinical trial · no report yet · Phase 3
KEYNOTE-866
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
- NCT03924856 ↗
- Completed
- Merck Sharp & Dohme LLC
- 19 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 10 | |
| X threads | 6 | |
| Podcasts | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy Versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-866)
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Bladder Cancer
- Interventions
- Pembrolizumab; Gemcitabine; Cisplatin; Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]); Placebo
- Arms
- Pembrolizumab + Gemcitabine + Cisplatin + Surgery · Experimental
- Placebo + Gemcitabine + Cisplatin + Surgery · Placebo comparator
- Enrollment
- 907
- Primary outcomes
- Event-Free Survival (EFS)
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Jun 13, 2019
- Primary completion
- Jan 26, 2026
- Results posted
- No
- Registry record
- NCT03924856 · updated Oct 8, 2026
Publications
linked from the registry- Galsky MD, Hoimes CJ, Necchi A, Shore N, Witjes JA, Steinberg G, Bedke J, Nishiyama H, Fang X, Kataria R, Sbar E, Jia X, Siefker-Radtke A. Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303. Future Oncol. 2021 Aug;17(24):3137-3150. doi: 10.2217/fon-2021-0273. Epub 2021 May 19. PubMed 34008425